Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q1 2026 Earnings Presentation
19 slides from Arcticzymes Technologies Asa's earnings presentation, May 7, 2026
Slide 1: Solid Start to 2026
May 7, 2026 Q1 2026 CEO Michael Akoh CFO Børge Sørvoll Solid Start to 2026 CCO Paul Blackburn
Slide 2: Agenda
Agenda 1 Q1 highlights and key takeaways 2 Commercial update 3 Financial performance 4 Ambition, Strategy and Executing on our priorities 5 Q&A
Slide 3: Building the Foundation: Strong Q1 Sets Up 2026
Q1 2026 · HIGHLIGHTS Building the Foundation: Strong Q1 Sets Up 2026 FINANCIAL PERFORMANCE STRATEGIC MILESTONES COMMERCIAL TOTAL REVENUE SALES REVENUE EBITDA CMD Validation Capital Markets Day — strong technology validation from key partners 35.0 MNOK 31.8 MNOK 1.6 MNOK IP European Patent Granted RN
Slide 4: EU patent granted
INT ELLECT U AL PROPERT Y 01 WHAT WAS GRANTED EU patent granted Novel RNA restriction enzyme family covering analytical, process development & manufacturing workflows for therapeutic RNA production. RNA restriction enzyme technology "We are building a strong IP foundation around innovative enzyme te
Slide 5: Independent Validation by Partners in Real conditions
Independent Validation by Partners in Real conditions Validated Performance, Growing Reach by partnering with leading research institutions WHERE WE STAND 2023 2024 2025 2026 Independent data foundation to quantify M-SAN’s commercial value: ~2× process yield improvement Long-Term Excellence Scientif
Slide 6: Commercial Update Q1 2026
Commercial Update Q1 2026
Slide 7: Q1 2026 Sales Highlights
Q1 2026 Sales Highlights Broad-Based Growth - Strongest Q1 on Record (ex-covid) Q1 2026 Total Revenue 31.8 MNOK 35 MNOK CER +36% YoY · +8.4 MNOK vs Q1 2025 Biomanufacturing Molecular Tools 15.1 MNOK 16.6 MNOK +11% YoY +72% YoY • Above 3-year average across both segments • 4 consecutive quarters of t
Slide 8: Biomanufacturing
Biomanufacturing M-SAN HQ Drives Growth - GMP Momentum Biomanufacturing 15.1 MNOK +11% YoY · M-SAN HQ franchise - 2nd-best quarter ever: 110% Growth GMP momentum: M-SAN HQ GMP +41% QoQ, reflecting continued commercial-stage adoption Customer mix: top-three global CDMOs led; smaller contributions fro
Slide 9: Molecular Tools
Molecular Tools Key-OEM-Led Growth with Healthy Underlying Demand Molecular Tools 16.6 MNOK +72% YoY dsDNases: +135% rSAP: +289% Cod UNG: +9% Top-five customers all Cod UNG buyers - three diagnostics platforms ramping Proteinase: Orders locked-in for the rest of 2026 from a US early-detection diagno
Slide 10: Commercial Commentary
Commercial Commentary Indicators Support Continued Momentum Operational Momentum Watchpoints • AOV +34% YoY - quality of revenue improving • Order phasing effects expected to normalize • +25 new paying customers in Q1; 169 paying throughH2 in East Coast customers (flat) • APAC Mol Tools soft; recove
Slide 11: Financial Performance
A. ArcticZymes A2X Technologies 7% /# Financial Performance ~ ~\ * _— i (A
Slide 12: Currency impact
USD/NOK Currency impact 12 11,5 Underlying growth despite headwinds 11 10,5 10 Norwegian krone continued strengthening 9,5 against the USD 9 Norwegian krone strengthened against the 2024 2025 2026 EURO in the Q1 2026. EUR/NOK 12,2 12 11,8 Adjusting revenues for constant currency: 11,6 11,4 Q1 2026 Q
Slide 13: Commercial execution in focus
Commercial execution in focus Expense development in alignment with plans Q1 Personnel expenses 2026 2025 Sales revenues 31,8 23,3 Continued reduction in capitalization Other revenues 3,3 1,6 Sum revenues 35,1 24,9 Full effect of 2025 commercial hires driving topline Cost of materials -1,4 -1,2 Chan
Slide 14: Margin improvement over last year
Margin improvement over last year Positive EBITDA Sales & EBITDA Q1 2026 2025 Sales Sales revenues 31,8 23,3 35 Other revenues 3,3 1,6 EBITDA 30 Sum revenues 35,1 24,9 25 Cost of materials -1,4 -1,2 Change in inventory -0,7 0,3 20 Personnel expenses -20,8 -18,8 Other operating expenses -10,6 -9,0 MN
Slide 15: Cash flow and short-term investments
Cash flow and short-term investments Robust 264 MNOK position secures commercial execution Cash and STI position 280 Short term investments (STI) 30 Net Cash (MNOK) 260 25 Changes in Cash and STI (MNOK) 240 20 Changes in cash and STI (MNOK) Net Cash (MNOK) 220 15 200 10 180 5 160 0 140 -5 Q1 2025 Q2
Slide 16: Strategy, Ambition and Priorities
01 Umbrella Strategy Customer focus & diversification 02 Strategic Pillars Molecular Tools · Viral Vectors · RNA · Channel Strategy, Ambition and Priorities 03 Financial Ambition Double-digit growth & disciplined execution Delivering on our strategic agenda
Slide 17: Building a Scalable Enzyme Platform
Building a Scalable Enzyme Platform Strategic pillars accelerating growth and resilience Umbrella Strategy Customer focused market approach Transition from product-oriented enzyme supplier, to a customer centric, application lead/solutions provider Create a wider base – diversification Increase the
Slide 18: Driving Scalable Profitable Growth
Driving Scalable Profitable Growth Financial ambition. Disciplined focused execution. OUR AMBITION OUR EXECUTION Core priorities (2026-2028): Sustainable double-digit growth, targeting outperformance of served markets: Scale a high-performance commercial engine Innovation through R&D and partner
Slide 19: Thank you Q & A
ArcticZymes Technologies *
ArcticZymes Technologies — Q1 2026 Earnings Presentation on 6ix